CuroGene Life Sciences Co., Ltd. is a pharmaceutical company founded in Korea aiming to be the preeminent partner for patients with eye
disorders through breakthrough developments in genetic biologics.
Close collaborations between CuroGene Life Sciences Co., Ltd. and experts in the field led to the discovery of novel target genes relating to wet
AMD (Age-related Macular Degeneration) and DR (Diabetic Retinopathy), and the development of a pipeline of gene therapeutics, consisting of
CRG-101, CRG-102, CRG-201 and CRG-202.
“First-in-Market” gene therapy products consisting of a recombinant
adeno-associated virus-delivered mTOR-inhibiting short hairpin RNA
that simultaneously blocks the activity of both mTOR complex 1 and 2.
Highly promising gene therapy products composed of a soluble VEGF
receptor-1 variant packaged in a recombinant adeno-associated